NCT07348510

Brief Summary

This work aims to investigate the diuretic effect of Aminophylline in comparison to Furosemide in adult patients undergoing cardiac surgical procedures.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
106

participants targeted

Target at P50-P75 for not_applicable

Timeline
2mo left

Started Jan 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress58%
Jan 2026Jul 2026

First Submitted

Initial submission to the registry

January 7, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 16, 2026

Completed
1 day until next milestone

Study Start

First participant enrolled

January 17, 2026

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 26, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 26, 2026

Last Updated

January 21, 2026

Status Verified

January 1, 2026

Enrollment Period

6 months

First QC Date

January 7, 2026

Last Update Submit

January 17, 2026

Conditions

Diuretic EffectAminophyllineFurosemideCardiac Surgical Procedures

Outcome Measures

Primary Outcomes (1)

  • Measurement of urine output

    Urine output will be measured at two hours after cardiopulmonary bypass.

    Two hours after cardiopulmonary bypass

Secondary Outcomes (6)

  • Measurement of urine output at completion of cardiopulmonary bypass

    48 hours after cardiopulmonary bypass

  • Urea level

    48 hours after cardiopulmonary bypass

  • Creatinine level

    48 hours after cardiopulmonary bypass

  • Lactate level

    48 hours after cardiopulmonary bypass

  • Estimated Glomerular Filtration Rate (eGFR)

    48 hours after cardiopulmonary bypass

  • +1 more secondary outcomes

Study Arms (2)

Aminophylline group (control group)

ACTIVE COMPARATOR

Patients will receive Aminophylline.

Drug: Aminophylline

Furosemide group

EXPERIMENTAL

Patients will receive furosemide.

Drug: Furosemide

Interventions

AminophyllineDRUG

Patients will receive Aminophylline.

Aminophylline group (control group)
FurosemideDRUG

Patients will receive furosemide.

Furosemide group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age from 18-65 years.
  • Both sexes.
  • All adult patients presenting for elective cardiac surgical procedures performed on cardiopulmonary bypass (Coronary artery bypass surgery, Cardiac valve repair and/or replacement, Repair of large septal defects, Repair and/or palliation of congenital heart defects, Transplantation, surgery of thoracic aneurysms.).
  • Body mass index (BMI) ranged between 20 and 40 kg/m2.

You may not qualify if:

  • Sensitivity or contraindication to Aminophylline or furosemide
  • Stage-5 chronic kidney disease (CKD) \[Glomerular filtration rate (GFR) of less than 15 mL/min\].
  • The presence of both factors (GFR less than 60 mL/min and albumin greater than 30 mg per gram of creatinine) along with abnormalities of kidney structure or function for greater than three months signifies chronic kidney disease.
  • Recipients of dialysis before surgery.
  • Recipients of solid-organ transplantation before surgery.
  • Emergency cardiac surgical procedures (e.g. left main coronary artery bypass graft, stuck valves, etc).
  • Patient refusal.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cairo University

Cairo, 12613, Egypt

RECRUITING

MeSH Terms

Interventions

AminophyllineFurosemide

Intervention Hierarchy (Ancestors)

EthylenediaminesDiaminesPolyaminesAminesOrganic ChemicalsTheophyllineXanthinesPurinonesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsDrug CombinationsPharmaceutical PreparationsSulfanilamidesSulfonamidesAmidesAniline CompoundsSulfonesSulfur Compounds

Central Study Contacts

Ahmed M Hassan, MSc

CONTACT

00201033752020ahm33hassan@gmail.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Lecturer of Anesthesia, surgical ICU and Pain management, Cairo University, Cairo, Egypt

Study Record Dates

First Submitted

January 7, 2026

First Posted

January 16, 2026

Study Start

January 17, 2026

Primary Completion (Estimated)

July 26, 2026

Study Completion (Estimated)

July 26, 2026

Last Updated

January 21, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will share

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Shared Documents
STUDY PROTOCOL
Time Frame
After the end of study for one year.
Access Criteria
The data will be available upon a reasonable request from the corresponding author.

Locations

EG(1)